• Net cash inflow from operating activities of $42k
• Quarterly receipts from customers increased by 35% to $369k
• Extraordinary general meeting to be held after Biortica complies with conditions

Bod Science Limited (Subject to a Deed of Company Arrangement) (ASX:BOD) has provided an update on its activities for the three-month period ended 31 March 2025 (Q3 FY2025). The company reported a net cash inflow from operating activities of $42k, a decrease of $9k on the previous quarter (Q2 FY2025). However, the Q3 FY2025 net cash inflow was $39k higher than the previous corresponding period (Q3 FY2024) due to increased receipts from customers and reduced staff costs, partially offset by reduced funding from Biortica. Quarterly receipts from customers were $369k, an increase of $96k (35%) on the last quarter (Q2 FY2025) and an increase of $238k (182%) on the previous corresponding period (Q3 FY2024). The increase was driven by increases in sales volumes from the introduction of new SKUs. The company made payments totaling $35k to related parties during the quarter, representing remuneration paid to a director. Bod Science has entered into a binding Share Purchase Agreement with the ordinary shareholders of Biortica, which is subject to conditions subsequent being met, together with the effectuation of the Deed of Company Arrangement (DOCA) and the company satisfying the re-compliance requirements with the ASX Listing Rules. The extraordinary general meeting of the shareholders is expected to be convened soon after Biortica complies with the conditions subsequent.

The company remains in suspension throughout the deed administration process and is awaiting Biortica to comply with the conditions subsequent to effectuate the DOCA and hold an extraordinary general meeting of shareholders.